DGAP-News: HAEMATO AG / Key word(s): Quarterly / Interim Statement/Quarter Results
30.11.2017 / 15:05
The issuer is solely responsible for the content of this announcement.
HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market has started. HAEMATO AG expects that first products will be launched in the coming year, which has already created the basis for further growth and additional income.
HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 72.5 million and an operating result (EBIT) of EUR 2.45 million in the third quarter of 2017. Sales thus increased by 2.4% in the comparable prior-year period. Within the first nine months of 2017, total revenue amounts to 211.3 million euros and EBIT to 5.64 million euros. The Management Board forecasts consolidated revenue of more than 280 million euros for the entire 2017 financial year.
HAEMATO AG, founded in 1993, is a pharmaceutical company. The emphasis of business activities lies on the growth markets of high-priced specialty pharmaceuticals. The focus lies on therapies for cancer, HIV and other chronic diseases.
HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG:
30.11.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|